Skip to content

Financial Information

This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQKPTI
Beta(0.17)
Shares Outstanding79.4M
Average Volume (10 days)3.0M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.41)
Sales (TTM)$2.95
Book Value (MRQ)($1.05)
Cash Flow (TTM)($1.49)
Cash (MRQ)$2.65

Analyst Views

Current Mean RecommendationBuy
Strong Buy2
 
Buy0
 
Hold5
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Richard Paulson
Director, President and CEO
(633)
Sell
May 4, 2022
Richard Paulson
Director, President and CEO
(27,869)
Sell
May 4, 2022
Sharon Shacham
President & CSO
60,000
Acquire
Mar 29, 2022
Sharon Shacham
Chief Scientific Officer
60,000
Acquire
Mar 29, 2022
Michael Glen Kauffman
Director
(6,226)
Sell
Feb 28, 2022

Recent SEC Filings

Insider Buy/Sell
May 20, 2022
Insider Buy/Sell
May 20, 2022
Insider Buy/Sell
May 20, 2022
Insider Buy/Sell
May 20, 2022
Insider Buy/Sell
May 20, 2022
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.